Daniel G. Stover

Aug 20, 2024 | nature.com | Daniel G. Stover |Roberto Salgado |Sherene Loi |W. Fraser Symmans |Charles M. Perou |Lisa Carey

AbstractAssociation of stromal tumor-infiltrating lymphocytes (sTILs) with survival outcomes among patients with metastatic breast cancer (MBC) remains unclear. The primary objective was to evaluate the association of sTILs with progression-free survival in randomized phase III trial CALGB 40502.

Jan 11, 2024 | targetedonc.com | Rohit Gosain |Rahul Gosain |Daniel G. Stover

Daniel Stover, MD, and the Oncology Brothers review results from HER2CLIMB-02, a randomized, double-blind phase 3 trial of tucatinib and T-DM1 in patients with previously treated HER2+ metastatic breast cancer.

Jan 11, 2024 | targetedonc.com | Rohit Gosain |Rahul Gosain |Daniel G. Stover

Following their review of clinical trial data presented at SABCS 2023, the Oncology Brothers discuss their key takeaways on recent updates in HER2+ breast cancer.

Jan 11, 2024 | targetedonc.com | Rohit Gosain |Rahul Gosain |Daniel G. Stover

Jan 11, 2024 | targetedonc.com | Rohit Gosain |Rahul Gosain |Daniel G. Stover

Sub-Analysis from APHINITY on Adjuvant Pertuzumab and Trastuzumab in HER2+ Breast CancerFollowing SABCS 2023, Daniel Stover, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss the benefit of adjuvant pertuzumab and trastuzumab according to ER and HER2 expression in patients with HER2+ breast cancer.